Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by:
Joyce F. Liu
Search for other papers by Joyce F. Liu in
Current site
Google Scholar
PubMed
Close
 MD, MPH
Restricted access

Treatment approaches for advanced ovarian cancer should consider several factors. Among the most important are platinum sensitivity, the status of BRCA and homologous recombination deficiency (HRD), and the changing indications for PARP inhibitors in recurrent disease and maintenance. PARP inhibitors have demonstrated clear benefit in patients with BRCA mutated tumors, especially in the first-line setting, and HRD testing can guide their use for patients without BRCA mutations. A new antibody–drug conjugate, mirvetuximab soravtansine, has been approved for use in a subset of patients with platinum-resistant disease. Newly diagnosed patients with advanced-stage ovarian, fallopian tube, or primary peritoneal cancers should always be evaluated by a gynecologic oncologist if possible.

Disclosure: Dr. Liu has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., EpsilaBio, Genentech, Inc., GlaxoSmithKline, Zentalis, and Regeneron Pharmaceuticals, Inc.

Correspondence: Joyce F. Liu, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Email: Joyce_Liu@dfci.harvard.edu
  • Collapse
  • Expand
  • 1.

    Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943953.

  • 2.

    Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249257.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Landrum LM, Java J, Mathews CA, et al. Prognostic factors for state III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013;130:1218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;120:12481259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:40594067.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 7.

    Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carninoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2019;37:13801390.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:24732483.

  • 9.

    Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;16:928936.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:24822496.

  • 11.

    Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:24952505.

  • 12.

    González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:23912402.

  • 13.

    Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ ENGOT-ov45). J Clin Oncol 2022;40:39523964.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023;41:609617.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:24162428.

  • 16.

    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:20392045.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel- carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779791.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open- label, phase 3 trial. Lancet Oncol 2020;21:699709.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Pignata S, Lorusso D, Joly F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol 2021;22:267276.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum- resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 2015;33:38363838.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:13821392.

  • 22.

    Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:12741284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:21542164.

  • 24.

    Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:19491961.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Matulonis UA, Herrstedt J, Oza A, et al. Final overall survival and long-term safety in the ENGOT-OV16/NOLA phase III trial of niraparib in patients with recurrent ovarian cancer. Presented at 2023 SGO Annual Meeting on Women’s Cancer; March 25–28, 2023; Tampa, Florida.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Coleman RL, Oza AM, Lorusso D, et al. Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Int J Gynecol Cancer 2022;32(Suppl 3):Abstract 0003.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Penson RT, Valencia RV, Cibula D, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol 2020;38:11641174.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open- label, randomised, phase 3 trial. Lancet Oncol 2022;23:465478.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Lii CL, Scambia G, Villalobos R, et al. Overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3. Int J Gynecol Cancer 2022;32(Suppl 3):Abstract LB001.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Oza AM, Lisyanskaya AS, Fedenko AA, et al. Overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. Ann Oncol 2022;33(Suppl 7):Abstract 5180.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol 2021;32:757765.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 2023;41:24362445.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1191 857 38
PDF Downloads 742 414 35
EPUB Downloads 0 0 0